Filing Flows › Interpace Biosciences (IDXG) › How it makes money
How Interpace Biosciences (IDXG) makes money
Interpace Biosciences (IDXG) made $9.1M of revenue in the second quarter 2026 (Q2 2026), -1% from a year earlier. Of every dollar of revenue, 62¢ was left as gross profit, 4¢ was left as operating profit, 2¢ was left as net earnings.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q2 2026 | % of revenue |
|---|---|---|
| Revenue | $9.1M | 100.0% |
| Cost of revenue | $3.5M | 38.1% |
| Gross profit | $5.7M | 61.9% |
| Operating expenses | $5.3M | 58.4% |
| Operating profit | $321K | 3.5% |
| Income tax | $64K | 0.7% |
| Net earnings | $158K | 1.7% |
| Operating cash flow | $98K | 1.1% |
| Free cash flow | $41K | 0.4% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q2 2026 | $9.1M | -1% |
| Q1 2026 | $9.0M | -22% |
| Q4 2025 | $9.2M | -26% |
| Q3 2025 | $8.8M | -29% |
| Q2 2025 | $9.2M | -23% |
| Q1 2025 | $11.5M | +13% |
| Q4 2024 | $12.4M | +22% |
From Interpace Biosciences' 10-Q filed Aug 10, 2026 (on EDGAR).
Questions
How does Interpace Biosciences make money?
Interpace Biosciences (IDXG) made $9.1M of revenue in the second quarter 2026 (Q2 2026), -1% from a year earlier. Of every dollar of revenue, 62¢ was left as gross profit, 4¢ was left as operating profit, 2¢ was left as net earnings.
What is Interpace Biosciences' profit margin?
Net earnings were $158K, 1.7% of revenue, in the second quarter 2026; the operating margin was 3.5%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.